

## **LIFE – FIVEFOLD IMPROVEMENT OF SENSOR CHEMISTRY SENSITIVITY**

**Bergen, Norway, 14 January 2025: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can announce significant improvement in glucose sensor sensitivity based on a new generation of Lifecare’s proprietary chemistry.**

The sensor sensitivity defines the potential to detect small changes of glucose levels and is an important performance parameter for CGM. Lifecare has managed to improve the sensitivity up to five-fold in laboratory experiments, compared to sensitivity achieved with our original chemistry.

This significant improvement in sensitivity is expected to beneficially impact Lifecare’s sensor in several aspects, whereof the most important is the potential for even more precise measurements providing increased accuracy of glucose monitoring. The accuracy of CGM’s is commonly referred to based on Mean Absolute Relative Difference (MARD), where a MARD lower than 10% indicates clinically acceptable accuracy.

In Q2 2023, data from Lifecare’s Clinical Development Study LFC-SEN-001 confirmed that our CGM system had achieved a MARD of 9,7%. The fivefold improvement of chemistry sensitivity in vitro leads to an expectation that the MARD can be significantly improved with the potential of being superior to MARD of available CGMs in the market.

In a product perspective the most prominent benefit of enhanced sensor sensitivity is improvement of the sensor signal-to-noise ratio. This leads to improved data readings and enhanced sensor performance, as well as simplifying of algorithms and data processing efficiency.

Consequently, the enhancement of sensitivity is expected to improve the precision and quality in glucose monitoring ensuring better outcomes for end-users, while simplification of sensor and software can be expected to reduce the manufacturing complexity yet enhance sensor reliability.

- All in all, the new chemistry marks a significant step forward for our sensor technology. It is expected to improve both performance and production, ensuring an enhanced user experience through increased accuracy and reduced complexity, says CEO Joacim Holter.

This announcement aligns with the operational review in the Q3 2024 report, which emphasized ongoing efforts to refine and strengthen processes.

- We are actively identifying opportunities to optimize product and production tolerances to meet the highest quality standards. This focused approach will drive substantial advancements in production consistency and product quality, reinforcing our commitment to delivering a high-quality implant to the market, adds Holter.

Introduction of this new generation of chemistry is not expected to affect the progress and production timeline of the Lifecare CGM sensor but will provide an improved product for the commercial market. Subject to validation we are assessing the potential for filing a new patent to protect this innovation.

Lifecare remains dedicated to pushing the boundaries of CGM technology, ensuring both exceptional product performance and user satisfaction.

### **About us**

Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("**CGM**") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("**NTR**") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

### **Contacts**

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42